Clinical Trial Update: Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing denosumab with zoledronic acid for bone disease in multiple myeloma completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Lesions
• Bone Metastases
• Multiple Myeloma

Drugs mentioned

• Denosumab (denosumab)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Amgen | Conditions: Cancer, Hematologic Malignancies | Phase 3 | Status: COMPLETED | Results posted: 2018-03-07